Master protocol to assess safety and recommended phase 2 dose of next generation NY-ESO-1–specific TCR T-cells in HLA-A*02 patients with synovial sarcoma or non-small cell lung cancer (Substudies 1 and 2).

Adam Jacob  Schoenfeld

(OPTIONAL) Uncompensated Relationships - Iovance Biotherapeutics

Mehmet  Altan

Consulting or Advisory Role - GlaxoSmithKline; Shattuck Labs

Research Funding - Adaptimmune (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Jounce Therapeutics (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Shattuck Labs (Inst)

Taofeek K.  Owonikoko

Stock and Other Ownership Interests  - CAMBIUM MEDICAL TECHNOLOGIES

Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; BerGenBio; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; Eisai; EMD Serono; G1 Therapeutics; Ipsen; Janssen; Jazz Pharmaceuticals; Lilly; MedImmune; Merck; Novartis; PharmaMar; Roche/Genentech; Takeda; Wells Fargo; Xcovery; Zentalis

Speakers' Bureau - Abbvie

Research Funding - Abbvie (Inst); Aeglea Biotherapeutics (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Corvus Pharmaceuticals; Eisai (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ipsen (Inst); Loxo/Lilly (Inst); Merck (Inst); Mersana (Inst); Meryx Pharmaceuticals (Inst); Novartis (Inst); Oncorus (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (Inst); Turning Point Therapeutics (Inst); United Therapeutics (Inst); WindMIL (Inst)

Patents, Royalties, Other Intellectual Property - DR4 Modulation and its Implications in EGFR-Target Cancer Therapy Ref:18089 PROV (CSP) United States Patent Application No. 62/670,210 June 26, 2018 (Co-Inventor) (Inst); OVERCOMING ACQUIRED RESISTANCE TO CHEMOTHERAPY TREATMENTS THROUGH SUPPRESSION OF STAT3 (Inst); SELECTIVE CHEMOTHERAPY TREATMENTS AND DIAGNOSTIC METHODS RELATED THERETO (Inst); Soluble FAS ligand as a biomarker of recurrence in thyroid cancer; provisional patent 61/727,519 (Inventor) (Inst)

Other Relationship - EMD Serono; Roche/Genentech

(OPTIONAL) Uncompensated Relationships - Reflexion Medical

Sandra P.  D'Angelo

Consulting or Advisory Role - Adaptimmune; Amgen; EMD Serono; GlaxoSmithKline; Immune design; Immunocore; Incyte; Merck; Nektar

Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); EMD Serono (Inst); Incyte (Inst); Merck (Inst); Nektar (Inst)

Travel, Accommodations, Expenses - Adaptimmune; EMD Serono; Nektar

Brian H.  Ladle

No Relationships to Disclose

Jonathan Christopher  Noujaim

Consulting or Advisory Role - Bayer

Kai  He

Consulting or Advisory Role - Bristol-Myers Squibb; Geneplus; Iovance Biotherapeutics; Mirati Therapeutics; Perthera

Research Funding - Abbvie (Inst); Adaptimmune (Inst); Amgen (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Iovance Biotherapeutics (Inst); Mirati Therapeutics (Inst)

David A.  Liebner

Consulting or Advisory Role - Blueprint Medicines; Epizyme; Foundation Medicine

Patents, Royalties, Other Intellectual Property - Co-holder of 2 patents ("Methods for Predicting Prognosis") that has been licensed to a private company, MatchTX, LLC.

Travel, Accommodations, Expenses - Blueprint Medicines; Epizyme; Foundation Medicine

Adrian G.  Sacher

Honoraria - Amgen; AstraZeneca; Bayer; BMS; Genentech/Roche; KisoJi Biotechnology; Merck; Pfizer; Tesaro

Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bayer; BMS; Genentech/Roche; KisoJi Biotechnology; Merck; Pfizer

Research Funding - AstraZeneca; Genentech/Roche

Travel, Accommodations, Expenses - AstraZeneca; Genentech/Roche; GlaxoSmithKline; Gritstone Bio; Pfizer

John B. A. G.  Haanen

Stock and Other Ownership Interests  - Neogene Therapeutics

Consulting or Advisory Role - Achilles Therapeutics (Inst); AIMM Therapeutics (Inst); Bristol-Myers Squibb (Inst); Immunocore (Inst); Ipsen (Inst); Molecular Partners (Inst); MSD Oncology (Inst); Neogene Therapeutics; Neon Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Third Rock Ventures (Inst)

Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Neon Therapeutics (Inst); Novartis (Inst)

Jeffrey  Yachnin

No Relationships to Disclose

Chao H.  Huang

Stock and Other Ownership Interests  - Vanguard Funds

Honoraria - Ipsen

Consulting or Advisory Role - Biodesix; Ipsen

Research Funding - Bayer (Inst); Benta Pharma Industries (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Regenxbio (Inst)

Brian Andrew  Van Tine

Leadership - Polaris

Consulting or Advisory Role - Adaptimmune; Apexigen; Bayer; Cytokinetics; Daiichi Sankyo; Deciphera; EMD Serono; Epizyme; GlaxoSmithKline; Lilly; Novartis; Pfizer

Speakers' Bureau - Adaptimmune; GlaxoSmithKline; Lilly; Novartis

Research Funding - GlaxoSmithKline; Merck; Pfizer; TRACON Pharma

Patents, Royalties, Other Intellectual Property - Accuronix Therapeutics- Licensing agreement. Sigma-2 Receptor Ligands and Therapeuticuses therefor (006766), • Modular Platform for Targeted Therapeutic Delivery (006755), • Sigma-2 Receptor Ligand Drug Conjugates as Antitumor Compounds, Methods of synth; Patent on ALEXT3102; Patent on the use of ME1 as a biomarker

Travel, Accommodations, Expenses - Adaptimmune; Advenchen Laboratories; Lilly

Aisha N.  Hasan

No Relationships to Disclose

Thomas H.  Faitg

Employment - GlaxoSmithKline

Stock and Other Ownership Interests  - GlaxoSmithKline

Emily  Butler

No Relationships to Disclose

Aiman  Shalabi

Employment - GlaxoSmithKline

Stock and Other Ownership Interests  - GlaxoSmithKline

Travel, Accommodations, Expenses - GlaxoSmithKline

Other Relationship - GlaxoSmithKline

Steven  Attia

Research Funding - AB Science (Inst); Adaptimmune (Inst); Advenchen Laboratories (Inst); Bavarian Nordic (Inst); Bayer (Inst); Blueprint Medicines (Inst); BTG (Inst); CBA Pharma (Inst); Deciphera (Inst); Desmoid Tumor Research Foundation; Epizyme (Inst); FORMA Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Gradalis (Inst); Immune Design (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Philogen (Inst); PTC Therapeutics (Inst); SpringWorks Therapeutics (Inst); Takeda (Inst); TRACON Pharma (Inst)

Dejka M.  Araujo

Research Funding - Adaptimmune (Inst); GlaxoSmithKline (Inst); Immatics (Inst)